| Non-inhibitory antibodies inducing increased emicizumab clearance in a severe hemophilia A inhibitor patient A Harroche, T Sefiane, M Desvages, D Borgel, D Lasne, C Casari, ... Haematologica 106 (8), 2287, 2021 | 12 | 2021 |
| Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models S Roullet, N Luc, J Rayes, J Solarz, D Disharoon, A Ditto, E Gahagan, ... Blood, The Journal of the American Society of Hematology 141 (23), 2891-2900, 2023 | 10 | 2023 |
| A reactive center loop–based prediction platform to enhance the design of therapeutic SERPINs W Sanrattana, T Sefiane, S Smits, ND van Kleef, MH Fens, PJ Lenting, ... Proceedings of the National Academy of Sciences 118 (45), e2108458118, 2021 | 6 | 2021 |
| A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a V Muczynski, A Smith, T Sefiane, OD Christophe, PJ Lenting, D Granger, ... Blood 140 (Supplement 1), 677-678, 2022 | 2 | 2022 |
| Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc T Sefiane, H Maynadié, CE Ettingshausen, V Muczynski, X Heiligenstein, ... Haematologica, 2023 | 1 | 2023 |
| Vers une meilleure compréhension des mécanismes moléculaires régissant l'action des thérapies non-substitutives dans l'hémophilie A et comparaison avec le facteur VIII T Sefiane Université Paris-Saclay, 2024 | | 2024 |
| OC 69.1 Thrombin-Mediated Autoregulation Restores Sensitivity to the Coagulation Feedback Loop et Reduces the Risk of Prothrombotic Events Associated with FVIII Mimetic Antibodies V Muczynski, A Smith, T Sefiane, O Christophe, P Lenting, D Granger, ... Research and Practice in Thrombosis and Haemostasis 7, 2023 | | 2023 |
| OC 50.4 Differences in bleeding profiles and venous clot structures between emicizumab and factor VIII-treated mice T Sefiane, V Muczynski, X Heiligenstein, OD Christophe, CV Denis, ... International Society of Thrombosis and Haemostasis ISTH, 2022 | | 2022 |
| Differences in bleeding profiles and venous clot structures between emicizumab and factor VIII-treated mice T Sefiane, V Muczynski, X Heiligenstein, OD Christophe, CV Denis, ... Congrès Français d’Hémostase (CFH), 2022 | | 2022 |
| Non-inhibitory antibodies inducing increased emicizumab clearance in a hemophilia A inhibitor patient A Harroche, T Sefiane, M Desvages, D Borgel, D Lasne, C Casari, ... | | |
